Cochrane · systematic review · CD012877
Adalimumab for maintenance of remission in Crohn's disease
Townsend, CM, Nguyen, TM, Cepek, J, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
8
No studies
5
Included studies
NR
No studies 5 · 38.5%Ungraded 0 · 0%Very low 1 · 7.7%Low 0 · 0%Moderate 5 · 38.5%High 2 · 15.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Adalimumab compared to placebo for maintenance of remission in Crohn's disease
Population: People with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to maintain clinical remission Adalimumab vs placebo | RR 0.7 [0.64, 0.77] | 3 studies · 683 participants | High |
Failure to maintain clinical remission Adalimumab vs placebo | RR 0.66 [0.52, 0.83] | 2 studies · 554 participants | Moderate Downgraded: inconsistency |
Failure to maintain endoscopic remission Adalimumab vs placebo | RR 0.74 [0.63, 0.87] | 1 study · 129 participants | Moderate Downgraded: imprecision |
Adverse events Adalimumab vs placebo | RR 1.01 [0.94, 1.09] | 4 studies · 1012 participants | High |
Serious adverse events Adalimumab vs placebo | RR 0.56 [0.39, 0.8] | 4 studies · 1012 participants | Moderate Downgraded: imprecision |
Withdrawals due to adverse events Adalimumab vs placebo | RR 0.59 [0.38, 0.91] | 4 studies · 1012 participants | Moderate Downgraded: imprecision |
Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure Adalimumab vs placebo | RR 0.76 [0.68, 0.85] | 2 studies · 302 participants | Moderate Downgraded: imprecision |
Adalimumab compared to active comparator for maintenance of remission in Crohn's disease
Population: People with quiescent Crohn's disease (ileocolic resection)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to maintain clinical remission Adalimumab vs active comparator | no estimate extracted | NR | No studies |
Failure to maintain endoscopic remission Adalimumab vs active comparator | RR 0.11 [0.02, 0.75] | 1 study · 51 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Adalimumab vs active comparator | no estimate extracted | NR | No studies |
Serious adverse events Adalimumab vs active comparator | no estimate extracted | NR | No studies |
Withdrawal due to adverse events Adalimumab vs active comparator | no estimate extracted | NR | No studies |
Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure Adalimumab vs active comparator | no estimate extracted | NR | No studies |